Biologic Product Launches Considering Patients, Prescribers, & Payers


Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at

SKU: 1429. Category: .

Product Description

Less than a decade ago, biologics were prescribed for only rare genetic diseases. Now these novel therapies are used to treat a host of more common conditions, including cancer, diabetes, multiple sclerosis, and rheumatoid arthritis. In fact, over 200 new therapies and vaccines are currently on the market, and more than 400 products targeting over 200 diseases are in clinical trials. Alongside the significant increase in the number of available therapies is an actual translation into market success. Worldwide, one out of eight prescriptions today is written for a biologic product. These therapies have certainly become a dominant player in the pharmaceutical industry and have undoubtedly made their mark on the world.
Organizations have thrust significant investments into the development and commercialization of biologic products to address the unmet needs of myriad patient populations and to fill gaps in product pipelines. For those companies and personnel who shift efforts from traditional, small-molecule products to more complex biologic products, there is a steep learning curve to climb, primarily because of dissimilarities between the two types. Biologics are substantially different from traditional therapies in multiple facets: 1) they are larger molecules and are often composed of a mixture of entities, 2) they require a more difficult administration through infusion or self-injection, and 3) they can cost up to 20 times more than non-biologic treatments. These distinct differences have given way to new questions among…